# INNOVATE Corp.: Form 10-Q for the period ended Sep 30, 2023

- Company: [INNOVATE Corp.](/companies/vate.md) (CIK 1006837)
- Form: 10-Q
- Filed: 2023-11-09
- Accepted by EDGAR: Nov 9, 2023, 16:27 ET
- Period: 2023-09-30
- Accession: 0001006837-23-000128
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006837/000100683723000128/vate-20230930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006837/000100683723000128/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $375.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $1.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-07-01 to 2023-09-30 | $316.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-01-01 to 2023-09-30 | $907.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-07-01 to 2023-09-30 | $58.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-01-01 to 2023-09-30 | $154.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2023-07-01 to 2023-09-30 | $43.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-01-01 to 2023-09-30 | $126.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | $10.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | $12.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-07-01 to 2023-09-30 | $17.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-01-01 to 2023-09-30 | $49.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | $3.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | −$7.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | −$25.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.36 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.36 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 78,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 78,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | −$34.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-07-01 to 2023-09-30 | $5.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $13.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2023-01-01 to 2023-09-30 | $1.8m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2023-09-30 | $55.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $552.5m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $1.10bn | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $557.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $1.22bn | us-gaap:Liabilities |
| Current portion of debt | at 2023-09-30 | $162.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2023-09-30 | −$157.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 107,938 characters.

You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023 (the "2022 Annual Report") and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2022 Annual Report as well as the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles accepted in the United States of America.

### Our Business and Our Operations

We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.

For additional information on our business, refer to Note 1. Organization and Business to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Cyclical Patterns

Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.

For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.

Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; financial condition of our customers and their access to capital; margins of projects performed during any particular period; rising interest rates and inflation; and economic, political and market conditions on a regional, national or global scale.

Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.

### Recent Developments

On July 23, 2023, we announced the unexpected passing of Wayne Barr, our President, Chief Executive Officer and Director. Mr. Barr had served as a director of INNOVATE since January 2014 and as CEO since November 2020. He previously served as Lead Director during March 2020 and as Interim CEO from June 2020 until November 2020 when he was appointed as the Company's permanent President and CEO. During his tenure as a director of INNOVATE, he has also served as Chair and/or as a member of several of the Board committees and as a director and/or officer of certain INNOVATE subsidiaries. Following Mr. Barr’s death, on July 25, 2023, Paul K. Voigt was named Interim Chief Executive Officer of the Company. Mr. Voigt has served as Senior Managing Director of Investments at Lancer Capital since 2019. From 2014 to 2018, Mr. Voigt served as Senior Managing Director of Investments of the Company and was involved with sourcing deals and capital raising for the Company.

On September 21, 2023, INNOVATE entered into a separation and release agreement with Suzi Herbst, our Chief Operating Officer. Pursuant to the agreement. Ms. Herbst's employment with the Company ceased on October 20, 2023 and the Company will pay Ms. Herbst severance payments and benefits.

We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer-term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use the available proceeds to pay down Broadcasting's Secured Notes.

Thus far in 2023, as part of our strategic process, we engaged in several transactions that had an effect on the results of operations and financial condition of our business and individual segments.

### Dispositions

#### Other

#### Sale of Remaining 19% Interest in HMN

On March 6, 2023, the Company, through New Saxon 2019 Limited (“New Saxon”), an indirect subsidiary of GMH, closed on the sale of its remaining 19% interest in HMN to subsidiaries and an affiliate of Hengtong Optic-Electric Co Ltd. The sale was consummated pursuant to the terms of a supplemental agreement entered into by the parties in June 2022. New Saxon received gross proceeds of $54.2 million, and interest income of $0.5 million, of which $4.4 million was withheld for a foreign tax payment. As of September 30, 2023, $15.9 million has been paid to GMH's non-controlling interest holders and redeemable non-controlling interest holders pursuant to the partnership agreement. New Saxon recognized a gain on sale of $12.2 million, which is reflected in Other income (expense), net in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2023.

### Debt Obligations and Financing

In 2023 thus far, we have refinanced some of our loans and obtained new capital financing. This financing helped us provide needed capital for our operations and the operations of our subsidiaries.

#### Infrastructure

Subsequent to quarter end, on November 2, 2023, UMB indicated its intent to extend the maturity date of the Revolving Line from May 31, 2024 to September 30, 2025. As part of the modification, the interest rate spread for the Revolving Line will be increased by 0.35% across all tiers, and the interest rate floor will be increased from 3.0% to 4.25%. No definitive agreements have been signed as of the filing date of this Form 10-Q Quarterly Report. There can be no assurances that the final signed agreements with UMB will close on the aforementioned terms or if at all.

#### Life Sciences

During the second and third quarters of 2023, R2 Technologies closed on an additional $2.7 million and $1.7 million, respectively, in 20% notes with Lancer. As of September 30, 2023, the total outstanding principal amount of 20% notes payable to Lancer was $17.4 million. In addition, during the third quarter of 2023, R2 entered into an amendment with Lancer to extend the maturity date of all outstanding 20% notes payable to Lancer to the earlier of November 15, 2023 or within 5 business days of the date on which R2 receives an aggregate $20.0 million from the consummation of a debt or equity financing.

#### Spectrum

On August 8, 2023, Broadcasting entered into an Eighth Amendment to Secured Notes with its lenders which extended the maturity date of its Senior Secured Notes aggregate principal amount of $69.7 million, from May 31, 2024 to August 15, 2024.

Subsequent to quarter end, on November 9, 2023, Broadcasting entered into a Ninth Amendment to its Secured Notes with its lenders which extended the maturity date of its Senior Secured Notes aggregate principal amount of $69.7 million, from August 15, 2024 to August 15, 2025. In exchange, INNOVATE has agreed to utilize proceeds from the sale of any of its existing operations, as allowable under the Company's current agreements and after all other required payments, for repayment of a portion of Broadcasting's Senior Secured Notes, plus an additional exit fee upon such a repayment of $1.0 million if repayment occurs by November 9, 2024, and $2.0 million if repayment occurs after that date. Upon payment of the exit fee, the lenders also agree to return their equity interests in HC2 Broadcasting Holdings, Inc. and its subsidiary equity interests.

#### Corporate

On April 25, 2023, INNOVATE extended the maturity date of its Revolving Credit Agreement with MSD PCOF Partners IX, LLC (the "Revolving Line of Credit") from February 23, 2024 to March 16, 2025, changed the interest benchmark rates from LIBOR-based to SOFR-based rates, and lowered the amount of net cash proceeds from certain asset sales in excess of which a prepayment is required from $50.0 million to $10.0 million. In March 2023, the Company paid down $15.0 million outstanding under the Revolving Line of Credit. On May 8, 2023, INNOVATE drew an additional $8.0 million under the Revolving Line of Credit, and on July 31, 2023, INNOVATE drew an additional $7.0 million under the Revolving Line of Credit, bringing the total outstanding balance to $20.0 million. Refer to 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

On May 9, 2023, INNOVATE issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million, in connection with the DBMGi Preferred Stock repurchase from CGIC. Refer to Footnote 15. Temporary Equity and Equity of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information. The CGIC Unsecured Note is due February 28, 2026, and bears interest at 9% per annum through May 8, 2024, 16% per annum from May 9, 2024 to May 8, 2025, and 32% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3 million or 12.5% of the proceeds from certain equity sales. Refer to 11. Debt

Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Equity Method Investments

In November 2022, MediBeacon amended its existing agreements with Huadong Medicine Co. Ltd ("Huadong"), to provide approximately $10 million in the first half of 2023, including $7.5 million or 50% of the remaining $15 million milestone investment due upon FDA approval of MediBeacon's TGFR at a pre-money valuation of approximately $400 million. On February 23, 2023, pursuant to its amended commercial partnership with Huadong, a publicly traded company on the Shenzhen Stock Exchange, MediBeacon issued $7.5 million of its preferred stock to Huadong in exchange for additional shares of preferred stock. As a result of this equity transaction, Pansend recognized a gain of $3.8 million in Other income (expense), net in the Condensed Consolidated Statements of Operations, which increased Pansend's basis in MediBeacon. Concurrently, Pansend recognized additional equity method losses of $3.8 million which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

On August 31, 2023 and September 13, 2023, Pansend issued $0.5 million and $0.5 million 12% convertible notes due September 2026 to MediBeacon, increasing the total outstanding principal amounts owed by MediBeacon to Pansend to $6.0 million. As a result of the additional $1.0 million 12% convertible notes issuances, Pansend recognized an additional $1.0 million of equity method losses which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

Subsequent to quarter end, on October 25, 2023, Pansend, issued an additional $0.8 million 12% convertible note to MediBeacon which is due October 24, 2026.

### Other

On December 30, 2022, the Company entered into a letter agreement with CGIC pursuant to which CGIC and its affiliates agreed to vote certain shares of the Company’s Series A-3 Convertible Participating Preferred Stock, par value $0.001 per share, and the Company’s Series A-4 Convertible Participating Preferred Stock, par value $0.001 per share, to the extent such shares result in CGIC beneficially owning more than 9.9% of the aggregate voting power of the Company, in the same manner as the majority of the holders holding less than 10% of the Company’s common stock, par value $0.001 per share, vote their shares with respect to any matter pursuant to which such shares are entitled to vote.

### Stockholders' Rights Agreement

On April 1, 2023, the Company entered into a Tax Benefits Preservation Plan (the "Plan") with ComputerShare Trust Company, N.A., as rights agent (the "Rights Agent"). The Plan is intended to help protect the Company's ability to use its tax net operating losses and other certain tax assets ("Tax Benefits") by deterring an "ownership change," as defined under Section 382 of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations thereunder (the "Code"), by a person or group of affiliated or associated persons from acquiring beneficial ownership of 4.9% or more of the outstanding common shares.

In connection with entering into the Plan, on April 1, 2023 the Board of Directors of the Company declared a dividend distribution of one right (a “Right”) for each outstanding share of common stock, par value $0.001 per share, of the Company (the “Common Stock”) to stockholders of record at the close of business on April 10, 2023 (the “Record Date”). Each Right is governed by the terms of the Plan and entitles the registered holder to purchase from the Company a unit consisting of one one-thousandth of a share (a “Unit”) of Series B Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at a purchase price of $15.00 per Unit, subject to adjustment (the “Purchase Price”). The Company had entered into a previous Tax Benefits Preservation Plan on August 30, 2021 (the “Prior Plan”), in order to help protect the Company’s ability to use its Tax Benefits by deterring an ownership change. The Prior Plan expired on March 31, 2023.

On June 15, 2023, holders of the Company’s Common Stock and Preferred Stock, voting as a single class and with the Preferred Stock voting on an as-converted basis, voted to ratify the amendment of the Tax Benefit Preservation Plan adopted by the Board of Directors on April 1, 2023, to extend the Final Expiration Date from October 1, 2023 to June 30, 2024, or such later date and time as may be subsequently approved.

Refer to Note 15. Temporary Equity and Equity of the Condensed Consolidated Financial Statements (Unaudited) included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

### Financial Presentation Background

In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three and nine months ended September 30, 2023 as compared to the three and nine months ended September 30, 2022.

### Results of Operations

The following table summarizes our results of operations and a comparison of the change between the periods as indicated (in millions):

| Revenue | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $369.3 | $412.7 | $(43.4) | $1,043.4 | $1,197.0 | $(153.6) |
| Life Sciences | 0.6 | 1.2 | (0.6) | 1.8 | 3.0 | (1.2) |
| Spectrum | 5.4 | 9.1 | (3.7) | 16.8 | 28.0 | (11.2) |
| Total revenue | $375.3 | $423.0 | $(47.7) | $1,062.0 | $1,228.0 | $(166.0) |
| Income (loss) from operations |  |  |  |  |  |  |
| Infrastructure | $20.9 | $18.5 | $2.4 | $41.9 | $42.2 | $(0.3) |
| Life Sciences | (3.3) | (5.5) | 2.2 | (11.6) | (15.7) | 4.1 |
| Spectrum | (2.1) | (0.6) | (1.5) | (3.2) | (4.1) | 0.9 |
| Other | — | (0.3) | 0.3 | (1.9) | (0.4) | (1.5) |
| Non-operating Corporate | (4.8) | (5.5) | 0.7 | (12.7) | (15.1) | 2.4 |
| Total income from operations | $10.7 | $6.6 | $4.1 | $12.5 | $6.9 | $5.6 |
| Interest expense | (17.1) | (13.3) | (3.8) | (49.0) | (38.4) | (10.6) |
| Loss from equity investees | (1.5) | (1.1) | (0.4) | (5.8) | (2.1) | (3.7) |
| Other income (expense), net | 0.4 | (0.9) | 1.3 | 17.2 | 0.5 | 16.7 |
| Loss from operations before income taxes | $(7.5) | $(8.7) | $1.2 | $(25.1) | $(33.1) | $8.0 |
| Income tax (expense) benefit | (1.1) | 2.0 | (3.1) | (3.2) | (1.6) | (1.6) |
| Net loss | $(8.6) | $(6.7) | $(1.9) | $(28.3) | $(34.7) | $6.4 |
| Net loss attributable to non-controlling interests and redeemable non-controlling interests | 1.6 | 1.3 | 0.3 | 2.4 | 4.5 | (2.1) |
| Net loss attributable to INNOVATE Corp. | $(7.0) | $(5.4) | $(1.6) | $(25.9) | $(30.2) | $4.3 |
| Less: Preferred dividends | 0.3 | 1.2 | (0.9) | 2.1 | 3.6 | (1.5) |
| Net loss attributable to common stockholders | $(7.3) | $(6.6) | $(0.7) | $(28.0) | $(33.8) | $5.8 |

*Revenue*: Revenue for the three months ended September 30, 2023 decreased $47.7 million to $375.3 million from $423.0 million for the three months ended September 30, 2022. The decrease was primarily driven by our Infrastructure segment, and, to a lesser extent, our Spectrum segment. The decrease at our Infrastructure segment was primarily driven by timing and size of projects, mostly from DBMG's commercial structural steel fabrication and erection business, as well as the industrial maintenance and repair business, while revenues at our Spectrum segment decreased primarily as a result of the termination of Network and its associated Azteca content on December 31, 2022.

Revenue for the nine months ended September 30, 2023 decreased $166.0 million to $1,062.0 million from $1,228.0 million for the nine months ended September 30, 2022. The decrease was primarily driven by our Infrastructure segment, and, to a lesser extent, our Spectrum segment. DBMG's commercial structural steel fabrication and erection business encountered customer and general contractor driven delays, resulting in the timing of work performed by DBMG to be delayed in the current period and lower revenue at the industrial maintenance and repair business. Revenues at our Spectrum segment decreased primarily as a result of the termination of Network and its associated Azteca content on December 31, 2022.

*Income from operations*: Income from operations for the three months ended September 30, 2023 increased $4.1 million to $10.7 million from $6.6 million for the three months ended September 30, 2022. The increase was due to a decrease in depreciation and amortization and a decrease in selling, general and administrative expenses ("SG&A"), which was partially offset by an increase in other operating expense. The overall decrease in depreciation and amortization was driven by Banker Steel, as certain intangibles were fully amortized subsequent to the comparable period. The overall decrease in SG&A was primarily driven by the decreases in bonus expense, salaries and benefits, as well as research and development costs and marketing costs as a result of cost reduction initiatives at our Life Sciences segment, as well as decreases at Spectrum from the termination of Network in December 2022, which were partially offset by an accounts receivable write-off of $2.2 million related to a customer bankruptcy and $1.1 million in restructuring costs primarily related to a foreign office closure in the current period at our Infrastructure segment. The overall increase in other operating expenses was driven by our Spectrum segment as a result of a decrease in FCC reimbursements received and impairment charges recorded in the current period related to certain redundant equipment and associated capitalized costs.

Income from operations for the nine months ended September 30, 2023 increased $5.6 million to $12.5 million from $6.9 million for the nine months ended September 30, 2022. The increase was due to decreases in depreciation and amortization, SG&A, and other operating expenses, which were partially offset by a net decrease in gross profit. The net decrease in depreciation and amortization was driven by Banker Steel, as certain intangible assets were fully amortized subsequent to the comparable period, and certain capitalized internal-use software included in PP&E within DBMG's commercial structural steel fabrication and erection business became fully depreciated subsequent to the comparable period. The net decrease in SG&A was primarily driven by the termination of Network at our Spectrum segment, decreases in compensation-related expenses as well as research and development and marketing costs at our Life Sciences segment, and decreases in SG&A expenses at our Non-Operating Corporate segment, which was partially offset by an accounts receivable write-off of $2.2 million related to a customer bankruptcy, $2.1 million in restructuring costs primarily related to a foreign office closure in the current period, and increases in compensation-related expenses at our Infrastructure segment, as well as an increase in expenses at our Other segment as a result of the sale of New Saxon's 19% investment in HMN. The net decrease in other operating expenses was driven by our Spectrum segment which impaired the Network PLA intangible in the comparable period which was partially offset by impairment charges recorded in the current period related to certain redundant equipment and associated capitalized costs and a decrease in FCC reimbursements received. The decrease in gross profit was primarily driven by our Spectrum segment's termination of Network, which was partially offset by an increase at Station group, which launched new markets and networks with its customers in the current period, and was also partially offset by an increase in gross profit at our Infrastructure segment driven by timing of higher margin projects.

*Interest expense*: Interest expense for the three months ended September 30, 2023 increased $3.8 million to $17.1 million from $13.3 million for the three months ended September 30, 2022. The increase was primarily attributable to higher interest rates, increased amortization of debt issuance costs on the debt, and higher outstanding principal balances at all segments, as a result of new debt issued subsequent to the comparable period.

Interest expense for the nine months ended September 30, 2023 increased $10.6 million to $49.0 million from $38.4 million for the nine months ended September 30, 2022. The increase was primarily attributable to higher interest rates, increased amortization of debt issuance costs on the debt, and higher outstanding principal balances at all segments, as a result of new debt issued subsequent to the comparable period.

*Loss from equity investees:* Loss from equity investees for the three months ended September 30, 2023 increased $0.4 million to $1.5 million from $1.1 million for the three months ended September 30, 2022. The increase in loss was primarily driven by the sale of our investment in HMN on March 6, 2023, which had income in the prior period, as well as higher equity method losses recorded from our investment in Triple Ring. This was partially offset by lower equity method losses from our investment in MediBeacon, as a result of suspended losses due to the investment's carrying amount being reduced to zero.

Loss from equity investees for the nine months ended September 30, 2023 increased $3.7 million to $5.8 million from $2.1 million for the nine months ended September 30, 2022. The increase in loss was primarily driven by our previous investment in HMN, which was sold on March 6, 2023, and had losses for the approximately two months of ownership in the current period, compared to net income for the nine months in the comparable period, as well as higher equity method losses in the current period from our investment in Triple Ring as a result of an unrepeated gain on debt extinguishment recognized by Triple Ring in the comparable period. This was partially offset by lower equity method losses from our investment in MediBeacon, as a result of suspended losses due to the investment's carrying amount being reduced to zero.

*Other income (expense), net:* Other income (expense), net for the three months ended September 30, 2023 increased $1.3 million to income of $0.4 million from other expense of $0.9 million for the three months ended September 30, 2022. Other income, net for the three months ended September 30, 2023 primarily consisted of foreign currency translation gains from our Infrastructure segment.

Other income, net for the nine months ended September 30, 2023 increased $16.7 million to $17.2 million from $0.5 million for the nine months ended September 30, 2022. Other income, net for the nine months ended September 30, 2023 primarily consisted of a gain on the sale of our equity investment in HMN of $12.2 million and a $3.8 million step-up gain from the increase in Pansend's basis as a result of MediBeacon issuing $7.5 million of its preferred stock to Huadong. Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information. Additionally contributing to Other income, net for the nine months ended September 30, 2023 is foreign currency translation gains from our Infrastructure segment and interest income earned on certain investments and receivables.

*Income tax (expense) benefit*: Income tax expense for the three months ended September 30, 2023 increased $3.1 million to $1.1 million from a $2.0 million benefit for the three months ended September 30, 2022. Income tax expense for the nine months ended September 30, 2023 increased $1.6 million to $3.2 million from $1.6 million for the nine months ended September 30, 2022. The increase was primarily driven by the net tax savings of $2.9 million from the CGIC consolidation on the 2021 tax return, which resulted in a partial release of the valuation in the comparable period. The income tax expense recorded for the three and nine months ended September 30, 2023 primarily relates to the tax expense as calculated under ASC 740 for taxpaying entities. Additionally, the tax benefits associated with losses generated by the INNOVATE Corp. U.S. consolidated income tax return and certain other businesses have been reduced by a full valuation allowance as we do not believe it is more-likely-than not that the losses will be utilized prior to expiration. The annual effective tax rate calculated for the interim tax provision includes a $1.1 million net tax benefit, consisting of a current tax expense of $4.4 million related to foreign tax payment and a deferred tax benefit of $5.5 million related to the reversal of the deferred tax liability associated with the $11.3 million put option agreement, both of which were related to the sale of New Saxon's 19% investment in HMN on March 6, 2023.

### Segment Results of Operations

In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs; (iii) asset impairment expense; (iv) accretion of asset retirement obligations; and (v) FCC reimbursements. Each table summarizes the results of operations of our operating segments and compares the amount of the change between the periods presented (in millions).

### Infrastructure Segment

|  | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $369.3 | $412.7 | $(43.4) | $1,043.4 | $1,197.0 | $(153.6) |
| Cost of revenue | 313.1 | 358.7 | (45.6) | 896.8 | 1,052.4 | (155.6) |
| Selling, general and administrative | 32.9 | 30.2 | 2.7 | 93.3 | 87.1 | 6.2 |
| Depreciation and amortization | 2.6 | 5.3 | (2.7) | 11.6 | 15.9 | (4.3) |
| Other operating loss (income) | (0.2) | — | (0.2) | (0.2) | (0.6) | 0.4 |
| Income from operations | $20.9 | $18.5 | $2.4 | $41.9 | $42.2 | $(0.3) |

*Revenue:* Revenue for the three months ended September 30, 2023 decreased $43.4 million to $369.3 million from $412.7 million for the three months ended September 30, 2022. The decrease was primarily driven by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business and lower revenue at the industrial maintenance and repair business. This was partially offset by an increase at Banker Steel and the construction modeling and detailing business due to timing and size of projects.

Revenue for the nine months ended September 30, 2023 decreased $153.6 million to $1,043.4 million from $1,197.0 million for the nine months ended September 30, 2022. The decrease was primarily driven by timing of projects at DBMG's commercial structural steel fabrication and erection business, which encountered customer and general contractor driven delays, resulting in the timing of work performed by DBMG to be delayed in the current period and lower revenue at the industrial maintenance and repair business. This was partially offset by Banker Steel and the construction modeling and detailing business due to the timing and size of projects.

*Cost of revenue:* Cost of revenue for the three months ended September 30, 2023 decreased $45.6 million to $313.1 million from $358.7 million for the three months ended September 30, 2022. The decrease was primarily driven by the timing of projects at DBMG's commercial structural steel fabrication and erection business and the industrial maintenance and repair business. This was partially offset by an increase at Banker Steel and the construction modeling and detailing business due to timing and size of projects.

Cost of revenue for the nine months ended September 30, 2023 decreased $155.6 million to $896.8 million from $1,052.4 million for the nine months ended September 30, 2022. The decrease was primarily driven by DBMG's commercial structural steel fabrication and erection business, which encountered customer and general contractor driven delays, resulting in the timing of work performed by DBMG to be delayed in the current period as well as the industrial maintenance and repair business. This was partially offset by an increase at Banker Steel and the construction modeling and detailing business due to timing and size of projects.

*Selling, general and administrative:* Selling, general and administrative expense for the three months ended September 30, 2023 increased $2.7 million to $32.9 million from $30.2 million for the three months ended September 30, 2022. The increase was primarily driven by an accounts receivable write-off of $2.2 million related to a customer bankruptcy, and a foreign office closure in the current period, as well as an increase in salaries and benefit expenses, which was partially offset by a decrease in professional fees.

Selling, general and administrative expense for the nine months ended September 30, 2023 increased $6.2 million to $93.3 million from $87.1 million for the nine months ended September 30, 2022. The increase was primarily driven by an accounts receivable write-off of $2.2 million related to a customer bankruptcy, and a foreign office closure in the current period, as well as increases in compensation-related expenses and restructuring costs, which were partially offset by a decrease in professional fees and travel and entertainment expenses.

*Depreciation and amortization:* Depreciation and amortization for the three months ended September 30, 2023 decreased $2.7 million to $2.6 million from $5.3 million for the three months ended September 30, 2022. The decrease was primarily driven by Banker Steel, as certain customer relationships and contracts intangibles were fully amortized subsequent to the comparable period.

Depreciation and amortization for the nine months ended September 30, 2023 decreased $4.3 million to $11.6 million from $15.9 million for the nine months ended September 30, 2022. The decrease was primarily driven by Banker Steel, as certain customer relationships and contracts intangibles were fully amortized subsequent to the comparable period. Additionally, certain capitalized internal-use software included in PP&E within DBMG's commercial structural steel fabrication and erection business became fully depreciated subsequent to the comparable period.

*Other operating loss (income)*: Other operating income for the nine months ended September 30, 2023 decreased $0.4 million to 0.2 million from $0.6 million for the nine months ended September 30, 2022. The decrease in income was primarily driven by gain on an unrepeated asset sale in the comparable period.

### Life Sciences Segment

|  | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $0.6 | $1.2 | $(0.6) | $1.8 | $3.0 | $(1.2) |
| Cost of revenue | 0.5 | 1.0 | (0.5) | 1.4 | 2.5 | (1.1) |
| Selling, general and administrative | 3.3 | 5.6 | (2.3) | 11.7 | 16.0 | (4.3) |
| Depreciation and amortization | 0.1 | 0.1 | — | 0.3 | 0.2 | 0.1 |
| Loss from operations | $(3.3) | $(5.5) | $2.2 | $(11.6) | $(15.7) | $4.1 |

*Revenue*: Revenue for the three months ended September 30, 2023 decreased $0.6 million to $0.6 million from $1.2 million for the three months ended September 30, 2022. The decrease in revenue was attributable to R2, primarily as a result of fewer sales of units and consumables outside the U.S., which was partially offset by an increase in upfront unit sales in the US.

Revenue for the nine months ended September 30, 2023 decreased $1.2 million to $1.8 million from $3.0 million for the nine months ended September 30, 2022. The decrease in revenue was attributable to R2, primarily as a result of fewer unit sales outside the U.S. due to payment delays resulting in shipping holds, which was partially offset by an increase in upfront unit sales in the US coupled with increased recurring revenues from consumable and subscription programs.

*Cost of revenue:* Cost of revenue for three months ended September 30, 2023 decreased $0.5 million to $0.5 million from $1.0 million for the three months ended September 30, 2022. Cost of revenue for the nine months ended September 30, 2023 decreased $1.1 million to $1.4 million from $2.5 million for the nine months ended September 30, 2022. The decrease in cost of revenue was attributable to R2, driven by a reduction in revenue.

*Selling, general and administrative*: Selling, general and administrative expense for the three months ended September 30, 2023 decreased $2.3 million to $3.3 million from $5.6 million for the three months ended September 30, 2022. Selling, general and administrative expense for the nine months ended September 30, 2023 decreased $4.3 million to $11.7 million from $16.0 million for the nine months ended September 30, 2022. The decrease was primarily driven by decreases from R2 in compensation-related expenses, as well as research and development costs and marketing expenses as a result of cost reduction initiatives.

### Spectrum Segment

|  | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $5.4 | $9.1 | $(3.7) | $16.8 | $28.0 | $(11.2) |
| Cost of revenue | 3.0 | 4.9 | (1.9) | 8.9 | 14.6 | (5.7) |
| Selling, general and administrative | 2.8 | 4.0 | (1.2) | 7.1 | 11.8 | (4.7) |
| Depreciation and amortization | 1.3 | 1.4 | (0.1) | 3.9 | 4.4 | (0.5) |
| Other operating loss (income) | 0.4 | (0.6) | 1.0 | 0.1 | 1.3 | (1.2) |
| Loss from operations | $(2.1) | $(0.6) | $(1.5) | $(3.2) | $(4.1) | $0.9 |

41

*Revenue:* Revenue for the three months ended September 30, 2023 decreased $3.7 million to $5.4 million from $9.1 million for the three months ended September 30, 2022. Revenue for the nine months ended September 30, 2023 decreased $11.2 million to $16.8 million from $28.0 million for the nine months ended September 30, 2022. The decrease was primarily driven by the elimination of advertising revenues at Azteca, which ceased operations on December 31, 2022. This was partially offset by an increase in station revenues, which launched new markets and networks with its customers in the current period.

*Cost of revenue:* Cost of revenue for the three months ended September 30, 2023 decreased $1.9 million to $3.0 million from $4.9 million for the three months ended September 30, 2022. Cost of revenue for the nine months ended September 30, 2023 decreased $5.7 million to $8.9 million from $14.6 million for the nine months ended September 30, 2022. The overall decrease was primarily driven by a decrease in advertising cost of revenue as a result of the termination of Azteca.

*Selling, general and administrative:* Selling, general and administrative for the three months ended September 30, 2023 decreased $1.2 million to $2.8 million from $4.0 million for the three months ended September 30, 2022. The decrease was primarily driven by the termination of Network, which was partially offset by an increase in severance expense at station group.

Selling, general and administrative expense for the nine months ended September 30, 2023 decreased $4.7 million to $7.1 million from $11.8 million for the nine months ended September 30, 2022. The decrease was primarily driven by the termination of Network, which was partially offset by an increase in employee-related costs and severance expense at station group

*Depreciation and amortization:* Depreciation and amortization expense for the nine months ended September 30, 2023 decreased $0.5 million to $3.9 million from $4.4 million for the nine months ended September 30, 2022. The decrease was primarily driven by the Program License Agreement ("PLA"), which was fully impaired in the comparable period.

*Other operating loss (income)*: Other operating loss (income) for the three months ended September 30, 2023 decreased $1.0 million to a loss of $0.4 million from income of $0.6 million for the three months ended September 30, 2022. The decrease was primarily related to a decrease in FCC reimbursements received and asset impairment charges recorded in the current period related to certain redundant equipment and associated capitalized costs.

Other operating loss for the nine months ended September 30, 2023 decreased $1.2 million to $0.1 million from $1.3 million for the nine months ended September 30, 2022. The decrease in loss was primarily related to the impairment of the PLA intangible in the comparable period, which was partially offset by asset impairment charges recorded in the current period related to certain redundant equipment and associated capitalized costs and a decrease in FCC reimbursements received.

### Non-operating Corporate

|  | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative | $4.8 | $5.5 | $(0.7) | $12.6 | $15.0 | $(2.4) |
| Depreciation and amortization | — | — | — | 0.1 | 0.1 | — |
| Loss from operations | $(4.8) | $(5.5) | $0.7 | $(12.7) | $(15.1) | $2.4 |

*Selling, general and administrative*: Selling, general and administrative expenses for the three months ended September 30, 2023 decreased $0.7 million to $4.8 million from $5.5 million for the three months ended September 30, 2022. The decrease in SG&A expenses was driven by severance related to the Company's former Chief Legal Officer accrued for in the prior period, a decrease in legal expenses, a decrease in bonus expense, and a decrease in salaries and benefits from a reduced headcount. The decreases were partially offset by severance related to the Company's former Chief Operating Officer accrued for in the current period and increased stock-based compensation expense from the acceleration of awards related to our former CEO.

Selling, general and administrative expenses for the nine months ended September 30, 2023 decreased $2.4 million to $12.6 million from $15.0 million for the nine months ended September 30, 2022. The decrease in SG&A expenses was driven by severance related to the Company's former Chief Legal Officer accrued in the prior period, a decrease in legal expenses, a decrease in bonus expense, a decrease in disposition and acquisition expenses and a decrease in salaries and benefits from a reduced headcount, as well as other unrepeated expenses related to the settlement with a former Chief Executive Officer recorded in the comparable period. The decreases were partially offset by severance related to the Company's former Chief Operating Officer accrued in the current period and increased stock-based compensation expense from the acceleration of awards related to our former CEO.

### Loss from Equity Investees

|  | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences | $(1.5) | $(2.5) | $1.0 | $(5.5) | $(5.8) | $0.3 |
| Other | — | 1.4 | (1.4) | (0.3) | 3.7 | (4.0) |
| Loss from equity investees | $(1.5) | $(1.1) | $(0.4) | $(5.8) | $(2.1) | $(3.7) |

*Life Sciences:* Loss from equity investees within our Life Sciences segment for the three months ended September 30, 2023 decreased $1.0 million to $1.5 million from $2.5 million for the three months ended September 30, 2022. The decrease in loss from equity investee was primarily due to lower equity method losses recognized from our investment in MediBeacon, which were partially offset by higher equity method losses recorded from our investment in Triple Ring. Pansend's basis in MediBeacon has been reduced to zero and Pansend has unrecognized losses from this investment. During the third quarter of 2023, as a result of an additional convertible notes investment in MediBeacon by Pansend, Pansend's basis in MediBeacon increased by $1.0 million and Pansend recognized an additional $1.0 million of equity method losses which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero. Pansend's carrying amount of its investment in MediBeacon remains at zero, which has resulted in fewer losses recognized than in the comparable period.

Loss from equity investees within our Life Sciences segment for the nine months ended September 30, 2023 decreased $0.3 million to $5.5 million from $5.8 million for the nine months ended September 30, 2022. The decrease in loss from equity investees was primarily due to lower equity method losses recognized from our investment in MediBeacon, which were partially offset by higher equity method losses recorded from our investment in Triple Ring. Pansend's basis in MediBeacon has been reduced to zero and Pansend has unrecognized losses from this investment. As a result of an additional equity investment made during the first quarter of 2023 by Huadong to MediBeacon, Pansend's basis in MediBeacon increased by $3.8 million, and Pansend issued an additional $1.0 million in convertible notes to MediBeacon during the third quarter of 2023, which also increased Pansend's basis in MediBeacon. Pansend recognized $4.8 million in equity method losses which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero. Pansend's carrying amount of its investment in MediBeacon remains at zero, which has resulted in fewer losses recognized than in the comparable period. The decrease in losses recognized from MediBeacon were partially offset by higher equity method losses from our investment in Triple Ring primarily driven by a gain on debt extinguishment recognized in the comparable period.

Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information on our Life Science segment's investment in MediBeacon.

*Other:* Income from equity investees within our Other segment for the three months ended September 30, 2023 decreased $1.4 million to zero from income of $1.4 million for the three months ended September 30, 2022. The decrease was driven by our previous investment in HMN, which was sold on March 6, 2023.

Loss from equity investees within our Other segment for the nine months ended September 30, 2023 increased $4.0 million to a loss of $0.3 million from income of $3.7 million for the nine months ended September 30, 2022. The increase in loss was driven by our previous investment in HMN, which was sold on March 6, 2023, and had losses for the approximately two months of ownership in the current period, compared to net income for the nine months in the comparable period.

Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information related to our Other segment's disposition of our equity investment in HMN.

### Non-GAAP Financial Measures and Other Information

#### Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, asset impairment expense and FCC reimbursements; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; legacy accounts receivable write-off; restructuring and exit costs; non-recurring items; and acquisition and disposition costs.

*(in millions)*

|  | Three months ended September 30, 2023 Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $10.8 | $(3.6) | $(6.5) | $(7.7) | $— | $(7.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 2.6 | 0.1 | 1.3 | — | — | 4.0 |
| Depreciation and amortization (included in cost of revenue) | 3.8 | — | — | — | — | 3.8 |
| Other operating (income) loss | (0.2) | — | 0.4 | — | — | 0.2 |
| Interest expense | 3.5 | 0.9 | 3.4 | 9.3 | — | 17.1 |
| Other (income) expense, net | (0.7) | (0.1) | 1.8 | (1.4) | — | (0.4) |
| Income tax expense (benefit) | 6.1 | — | — | (5.0) | — | 1.1 |
| Non-controlling interest | 1.0 | (1.8) | (0.8) | — | — | (1.6) |
| Share-based compensation expense | — | 0.2 | — | 0.6 | — | 0.8 |
| Legacy accounts receivable write-off | 2.2 | — | — | — | — | 2.2 |
| Restructuring and exit costs | 1.1 | — | 0.1 | — | — | 1.2 |
| Acquisition and disposition costs | 0.6 | — | — | 0.1 | — | 0.7 |
| Adjusted EBITDA | $30.8 | $(4.3) | $(0.3) | $(4.1) | $— | $22.1 |

*(in millions)*

|  | Three months ended September 30, 2022 Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $10.4 | $(5.5) | $(1.4) | $(9.6) | $0.7 | $(5.4) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 5.3 | 0.1 | 1.4 | — | — | 6.8 |
| Depreciation and amortization (included in cost of revenue) | 3.9 | — | — | — | — | 3.9 |
| Other operating income | — | — | (0.6) | — | — | (0.6) |
| Interest expense | 2.6 | 0.2 | 2.2 | 8.3 | — | 13.3 |
| Other (income) expense, net | (0.6) | (0.3) | (1.1) | 2.9 | — | 0.9 |
| Income tax expense (benefit) | 5.0 | — | — | (7.0) | — | (2.0) |
| Non-controlling interest | 1.0 | (2.2) | (0.4) | — | 0.3 | (1.3) |
| Share-based compensation expense | — | 0.1 | — | 0.3 | — | 0.4 |
| Acquisition and disposition costs | — | — | 0.2 | 0.1 | 0.1 | 0.4 |
| Adjusted EBITDA | $27.6 | $(7.6) | $0.3 | $(5.0) | $1.1 | $16.4 |

*Infrastructure:* Net income from our Infrastructure segment for the three months ended September 30, 2023 increased $0.4 million to $10.8 million from $10.4 million for the three months ended September 30, 2022. Adjusted EBITDA from our Infrastructure segment for the three months ended September 30, 2023 increased $3.2 million to $30.8 million from $27.6 million for the three months ended September 30, 2022. The increase in Adjusted EBITDA was primarily driven by timing of higher margin projects at DBMG's commercial structural steel fabrication and erection business, increased contributions from the construction modeling and detailing business, a decrease in recurring SG&A expenses, as well as increased contributions from the industrial maintenance and repair business. This was partially offset by lower contributions from Banker Steel due to timing and size of projects.

*Life Sciences:* Net loss from our Life Sciences segment for the three months ended September 30, 2023 decreased $1.9 million to $3.6 million from $5.5 million for the three months ended September 30, 2022. Adjusted EBITDA loss from our Life Sciences segment for the three months ended September 30, 2023 decreased $3.3 million to $4.3 million from $7.6 million for the three months ended September 30, 2022. The decrease in Adjusted EBITDA loss was primarily due to a decrease in SG&A expenses at R2, driven by a decrease in compensation-related expenses, research and development and marketing costs as a result of cost reduction initiatives, as well as lower equity method losses recognized from Pansend's investment in MediBeacon as a result of suspended losses due to the investment's carrying amount being reduced to zero. This was partially offset by net higher equity method losses recorded from our investment in Triple Ring.

*Spectrum:* Net loss from our Spectrum segment for the three months ended September 30, 2023 increased $5.1 million to $6.5 million from $1.4 million for the three months ended September 30, 2022. Adjusted EBITDA from our Spectrum segment for the three months ended September 30, 2023 decreased $0.6 million to a loss of $0.3 million from income of $0.3 million for the three months ended September 30, 2022. The decrease in Adjusted EBITDA was primarily due to an increase in SG&A expenses at station group, driven by an increase in severance and salaries and benefit related expenses.

*Non-operating Corporate:* Net loss from our Non-operating Corporate segment for the three months ended September 30, 2023 decreased $1.9 million to $7.7 million from $9.6 million for the three months ended September 30, 2022. Adjusted EBITDA loss from our Non-operating Corporate segment for the three months ended September 30, 2023 decreased $0.9 million to $4.1 million from $5.0 million for the three months ended September 30, 2022. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in legal expenses, and decreases in bonus expense, salaries and benefits from reduced headcount, as well as a net decrease in severance expense, which related to the Company's former Chief Operating Officer in the current period and to the Company's former Chief Legal Officer in the prior period.

*Other and Eliminations:* Net income from our Other and Eliminations segment for the three months ended September 30, 2023 decreased $0.7 million to zero from $0.7 million for the three months ended September 30, 2022. Adjusted EBITDA from our Other segment for the three months ended September 30, 2023 decreased $1.1 million to zero from $1.1 million for the three months ended September 30, 2022. The decrease in Adjusted EBITDA was primarily driven by the elimination of equity method income from our investment in HMN, which was sold on March 6, 2023. Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information related to our Other segment's disposition of our equity investment in HMN.

*(in millions)*

|  | Nine months ended September 30, 2023 Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $19.8 | $(9.3) | $(16.8) | $(27.8) | $8.2 | $(25.9) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 11.6 | 0.3 | 3.9 | 0.1 | — | 15.9 |
| Depreciation and amortization (included in cost of revenue) | 11.7 | 0.1 | — | — | — | 11.8 |
| Other operating (income) loss | (0.2) | — | 0.1 | — | — | (0.1) |
| Interest expense | 10.3 | 2.1 | 10.0 | 26.6 | — | 49.0 |
| Other (income) expense, net | (1.2) | (4.1) | 5.5 | (4.9) | (12.5) | (17.2) |
| Income tax expense (benefit) | 11.0 | — | — | (6.6) | (1.2) | 3.2 |
| Non-controlling interest | 1.9 | (5.6) | (2.0) | — | 3.3 | (2.4) |
| Share-based compensation expense | — | 0.5 | — | 1.5 | — | 2.0 |
| Legacy accounts receivable write-off | 2.2 | — | — | — | — | 2.2 |
| Restructuring and exit costs | 2.1 | — | 0.1 | — | — | 2.2 |
| Acquisition and disposition costs | 1.4 | — | 0.1 | 0.1 | 1.2 | 2.8 |
| Adjusted EBITDA | $70.6 | $(16.0) | $0.9 | $(11.0) | $(1.0) | $43.5 |

*(in millions)*

|  | Nine months ended September 30, 2022 Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $23.3 | $(14.9) | $(10.5) | $(30.4) | $2.3 | $(30.2) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 15.9 | 0.2 | 4.4 | 0.1 | — | 20.6 |
| Depreciation and amortization (included in cost of revenue) | 11.2 | — | — | — | — | 11.2 |
| Other operating (income) loss | (0.6) | — | 1.3 | — | — | 0.7 |
| Interest expense | 7.0 | 0.2 | 6.1 | 25.1 | — | 38.4 |
| Other (income) expense, net | (1.9) | (0.4) | 1.8 | — | — | (0.5) |
| Income tax expense (benefit) | 11.4 | — | — | (9.8) | — | 1.6 |
| Non-controlling interest | 2.3 | (6.3) | (1.5) | — | 1.0 | (4.5) |
| Share-based compensation expense | — | 0.3 | — | 1.4 | — | 1.7 |
| Non-recurring items | 0.1 | — | — | — | — | 0.1 |
| Acquisition and disposition costs | 0.3 | — | 0.4 | 0.6 | (0.4) | 0.9 |
| Adjusted EBITDA | $69.0 | $(20.9) | $2.0 | $(13.0) | $2.9 | $40.0 |

45

*Infrastructure:* Net income from our Infrastructure segment for the nine months ended September 30, 2023 decreased $3.5 million to $19.8 million from $23.3 million for the nine months ended September 30, 2022. Adjusted EBITDA from our Infrastructure segment for the nine months ended September 30, 2023 increased $1.6 million to $70.6 million from $69.0 million for the nine months ended September 30, 2022. The increase in Adjusted EBITDA was primarily driven by DBMG's commercial structural steel fabrication and erection business and increased contribution from the construction modeling and detailing business. While the commercial structural steel fabrication and erection business experienced customer and general contractor driven delays in the current period that impacted its revenue, Adjusted EBITDA saw margin improvement as projects completed in the comparable period, which had lower margins due to market pressure on point-of-sale project margins during the COVID-19 pandemic, were replaced with more recent projects with higher point-of-sale margins in the current period. This was partially offset by lower contributions from Banker Steel and the industrial maintenance and repair businesses due to the timing of projects, as well as an increase in recurring SG&A, primarily compensation-related expenses.

*Life Sciences:* Net loss from our Life Sciences segment for the nine months ended September 30, 2023 decreased $5.6 million to $9.3 million from $14.9 million for the nine months ended September 30, 2022. Adjusted EBITDA loss from our Life Sciences segment for the nine months ended September 30, 2023 decreased $4.9 million to $16.0 million from $20.9 million for the nine months ended September 30, 2022. The decrease in Adjusted EBITDA loss was primarily due a decrease in SG&A expenses at R2, driven by a decrease in compensation-related expenses, research and development and marketing costs as a result of cost reduction initiatives, as well as lower equity method losses recognized from our investment in MediBeacon in the current period, as a result of suspended losses due to the investment's carrying amount being reduced to zero. The decrease was partially offset by higher equity method losses from our investment in Triple Ring driven by a gain on debt extinguishment recognized in the comparable period.

*Spectrum:* Net loss from our Spectrum segment for the nine months ended September 30, 2023 increased $6.3 million to $16.8 million from $10.5 million for the nine months ended September 30, 2022. Adjusted EBITDA from our Spectrum segment for the nine months ended September 30, 2023 decreased $1.1 million to $0.9 million from $2.0 million for the nine months ended September 30, 2022. The decrease in Adjusted EBITDA was primarily due to an increase in SG&A expenses at station group, driven by an increase in salaries and benefits and severance expense, which were partially offset by the elimination of Network's EBITDA losses in the comparable period as a result of the termination of Network and an increase in station revenues, which launched new markets and networks with its customers in the current period.

*Non-operating Corporate:* Net loss from our Non-operating Corporate segment for the nine months ended September 30, 2023 decreased $2.6 million to $27.8 million from $30.4 million for the nine months ended September 30, 2022. Adjusted EBITDA loss from our Non-operating Corporate segment for the nine months ended September 30, 2023 decreased $2.0 million to $11.0 million from $13.0 million for the nine months ended September 30, 2022. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in legal and settlement expenses, decreases in bonus expense, salaries and benefits from reduced headcount, as well as a net decrease in severance expense, which related to the Company's former Chief Operating Officer in the current period and to the Company's former Chief Legal Officer in the prior period.

*Other and Eliminations:* Net income from our Other and Eliminations segment for the nine months ended September 30, 2023 increased $5.9 million to $8.2 million from $2.3 million for the nine months ended September 30, 2022. Adjusted EBITDA from our Other segment for the nine months ended September 30, 2023 decreased $3.9 million to an Adjusted EBITDA loss of $1.0 million from Adjusted EBITDA income of $2.9 million for the nine months ended September 30, 2022. The decrease in Adjusted EBITDA was driven by reduced contribution from HMN, which was sold on March 6, 2023 and severance related expense at TIC Holdco, Inc.

Adjusted EBITDA by segment is summarized as follows:

| (in millions): | Three Months Ended September 30, 2023 | 2022 | Increase / (Decrease) | Nine Months Ended September 30, 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $30.8 | $27.6 | $3.2 | $70.6 | $69.0 | $1.6 |
| Life Sciences | (4.3) | (7.6) | 3.3 | (16.0) | (20.9) | 4.9 |
| Spectrum | (0.3) | 0.3 | (0.6) | 0.9 | 2.0 | (1.1) |
| Non-operating Corporate | (4.1) | (5.0) | 0.9 | (11.0) | (13.0) | 2.0 |
| Other and Eliminations | — | 1.1 | (1.1) | (1.0) | 2.9 | (3.9) |
| Adjusted EBITDA | $22.1 | $16.4 | $5.7 | $43.5 | $40.0 | $3.5 |

46

### Backlog

Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.

#### Infrastructure Segment

As of September 30, 2023, DBMG's backlog was $1,265.5 million, consisting of $1,154.0 million under contracts or purchase orders and $111.5 million under letters of intent or notices to proceed. Approximately $571.4 million, representing 45.2% of DBMG’s backlog as of September 30, 2023, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG includes an additional $8.2 million in its backlog that is not included in the remaining unsatisfied performance obligations disclosed in Note 3. Revenue and Contracts in Process of the Condensed Consolidated Financial Statements (Unaudited) included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information. This additional backlog includes commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.

### Liquidity and Capital Resources

### Short- and Long-Term Liquidity Considerations and Risks

Our Non-Operating Corporate segment consists of holding companies, and its liquidity needs are primarily for interest payments on its 2026 Senior Secured Notes, 2026 Convertible Notes, Revolving Line of Credit, CGIC Unsecured Note, and dividend payments on its Preferred Stock and recurring operational expenses.

On a consolidated basis, as of September 30, 2023, we had $55.7 million of cash and cash equivalents, excluding restricted cash, compared to $80.4 million as of December 31, 2022. On a stand-alone basis, as of September 30, 2023, our Non-operating Corporate segment had cash and cash equivalents, excluding restricted cash, of $1.5 million compared to $9.1 million at December 31, 2022.

Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment, over-the-air ("OTA") broadcast station equipment, development of back-office systems, operating costs and expenses, and income taxes.

As of September 30, 2023, we had $756.8 million of principal indebtedness on a consolidated basis compared to $725.3 million as of December 31, 2022, a net increase of $31.5 million, which was primarily due to the issuance of the $35.1 million CGIC Unsecured Note, the issuance of additional debt at R2 Technologies in principal amount of $6.6 million, partially offset by a $10.2 million net decrease in debt at our Infrastructure segment.

As of September 30, 2023, on a stand-alone basis, our Non-operating Corporate segment indebtedness increased to $436.9 million from $401.8 million as of December 31, 2022, an increase of $35.1 million, attributable to the issuance of the $35.1 million CGIC Unsecured Note. As of September 30, 2023, our Non-Operating Corporate segment's stand-alone indebtedness consists of the $330.0 million aggregate principal amount of 2026 Senior Secured Notes, $51.8 million aggregate principal amount of 2026 Convertible Notes, $35.1 million principal amount CGIC Unsecured Note and $20.0 million aggregate principal amount drawn on the Revolving Line of Credit. Our Non-operating Corporate segment is required to make semi-annual interest payments on the 2026 Senior Secured Notes and 2026 Convertible Notes on February 1st and August 1st of each year, quarterly interest payments on the Revolving Line of Credit, and monthly interest payments on the CGIC Unsecured Note. As described below, the interest rate on the CGIC Unsecured Note will increase from 9% per annum to 16% per annum on May 9, 2024 and from 16% per annum to 32% per annum on May 9, 2025.

We are required to make dividend payments on our outstanding Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year.

Our Non-Operating Corporate segment received $7.0 million and $18.3 million in tax sharing payments from its Infrastructure segment for the three and nine months ended September 30, 2023, respectively.

We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries. In the future, we may also choose to sell assets or certain investments to generate cash.

On March 15, 2023, DBMGi received a redemption notice from CGIC, the holder of the Series A Fixed-to-Floating Rate Perpetual Preferred Stock of DBMGi (the “DBMGi Preferred Stock”) requesting that DBMGi redeem 41,820.25 shares of DBMGi Preferred Stock, representing all of the issued and outstanding shares of DBMGi Preferred Stock, within 60 days of the notice, or by May 15, 2023. On May 9, 2023, the Company entered into a Stock Purchase Agreement and Subordinated Unsecured Promissory Note with CGIC whereby the Company agreed to purchase the 41,820.25 shares of DBMGi Preferred Stock for full satisfaction of the redemption notice. In full consideration of the DBMGi Preferred Stock as well as an accrued dividend of $0.4 million, the Company paid CGIC $7.1 million on May 9, 2023, and issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Unsecured Note is due February 28, 2026, and bears interest at 9% per annum through May 8, 2024, 16% per annum from May 9, 2024 to May 8, 2025, and 32% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3 million or 12.5% of the proceeds from certain equity sales. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association. The foregoing is a summary only and does not purport to be a complete description of all of the terms, provisions, covenants, and agreements contained in the Stock Purchase Agreement and Subordinated Unsecured Promissory Note, and is subject to and qualified in its entirety by reference to the full text of the Stock Purchase Agreement and Subordinated Unsecured Promissory Note, which were filed with our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2023, as Exhibits 10.5 and 10.6, respectively, and are incorporated herein by reference. On May 8, 2023, INNOVATE drew an additional $8.0 million under the Revolving Credit Agreement. Additionally, on July 31, 2023, INNOVATE drew an additional $7.0 million under the Revolving Credit Agreement, increasing the outstanding balance to $20.0 million as of September 30, 2023.

On November 7, 2023, Lancer Capital, LLC (“Lancer”), a related party and an entity controlled by Avram A. Glazer, the Chairman of INNOVATE's Board of Directors and a beneficial owner of the Company, provided a letter of support for up to $35.0 million to the Company expressing Lancer’s continued support for the Company and Lancer’s intent to facilitate the provision of additional funding as reasonably requested by the Board through the earlier of November 30, 2024 or the date on which the Company closes any sale or series of sales of debt or equity security raised of the Company, both as defined in the letter, resulting in aggregate net proceeds to the Company of greater than or equal to $35.0 million. Management believes that with the available cash on hand, available borrowings under the Revolving Line of Credit, distributions from the Company’s subsidiaries and the letter of support from Lancer, the Company will be able to meet its obligations for at least the next twelve months from the issuance of the Condensed Consolidated Financial Statements.

The ability of INNOVATE’s subsidiaries to make distributions to INNOVATE is subject to numerous factors, including restrictions contained in each subsidiary’s financing agreements, availability of sufficient funds at each subsidiary and the approval of such payment by each subsidiary’s board of directors, which must consider various factors, including general economic and business conditions, tax considerations, strategic plans, financial results and condition, expansion plans, any contractual, legal or regulatory restrictions on the payment of dividends, and such other factors each subsidiary’s board of directors considers relevant. Although the Company believes, that it will be able, to the extent needed, to raise additional debt or equity capital, refinance indebtedness or preferred stock, enter into other financing arrangements or engage in asset sales and sales of certain investments sufficient to fund any cash needs that we are not able to satisfy with the funds on hand or expected to be provided by our subsidiaries, there can be no assurance that it will be able to do so on terms satisfactory to the Company, if at all. Such financing options, if pursued, may also ultimately have the effect of negatively impacting our liquidity profile and prospects over the long-term and dilute the holders of common stock. Our ability to sell assets and certain of our investments to meet our existing financing needs may also be limited by our existing financing instruments. In addition, the sale of assets or the Company’s investments may also make the Company less attractive to potential investors or future financing partners.

### Capital Expenditures

Capital expenditures are set forth in the table below (in millions):

|  | Three Months Ended September 30, 2023 | 2022 | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Infrastructure | $5.5 | $6.9 | $12.5 | $13.5 |
| Life Sciences | — | 0.2 | 0.3 | 0.3 |
| Spectrum | 0.2 | 0.4 | 0.8 | 2.5 |
| Non-operating Corporate | — | — | 0.3 | — |
| Total | $5.7 | $7.5 | $13.9 | $16.3 |

48

### Indebtedness

### Non-Operating Corporate

#### 2026 Senior Secured Notes

On February 1, 2021, our Non-Operating Corporate segment repaid the senior secured notes that were due in 2021 and issued $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"). The 2026 Senior Secured Notes mature on February 1, 2026, and accrue interest at a rate of 8.50% per year, which interest is paid semi-annually on February 1st and August 1st of each year. For additional information on the terms and conditions of the 2026 Senior Secured Notes, including guarantees, ranking and collateral, refer to Note 13. Debt Obligations to the Consolidated Financial Statements included in our 2022 Annual Report, which was filed with the SEC on March 14, 2023.

#### 2026 Convertible Notes

As of September 30, 2023, we had $51.8 million 2026 Convertible Notes outstanding. The 2026 Convertible Notes were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). The 2026 Convertible Notes mature on August 1, 2026 unless earlier converted, redeemed or purchased. The 2026 Convertible Notes accrue interest at a rate of 7.5% per year, which interest is paid semi-annually on February 1st and August 1st of each year. For additional information on the terms and conditions of the 2026 Convertible Notes, including optional redemption, conversion rights guarantees, ranking and collateral, refer to Note 13. Debt Obligations to the Consolidated Financial Statements included in our 2022 Annual Report, which was filed with the SEC on March 14, 2023.

Our debt contains customary events of default which could, subject to certain conditions, cause the 2026 Senior Secured Notes and the 2026 Convertible Notes to become immediately due and payable.

#### Revolving Credit Agreement

We have a revolving credit agreement with MSD PCOF Partners IX, LLC which has a maximum commitment of $20.0 million ("Revolving Line of Credit"), of which $20.0 million had been drawn as of September 30, 2023. Interest on loans under the Revolving Line of Credit accrues at SOFR plus 5.75% plus and is payable quarterly. The maturity date of the Revolving Line of Credit is March 16, 2025. The amount outstanding under the Revolving Line of Credit is subject to mandatory prepayment from the net cash proceeds from certain asset sales in excess of $10.0 million.

In March 2023, the Company paid down $15.0 million of the Revolving Credit Agreement, and in May and July 2023, INNOVATE drew an aggregate additional $15.0 million under the Revolving Credit Agreement, bringing the outstanding balance to $20.0 million as of September 30, 2023.

For additional information on the terms and conditions of the Revolving Credit Facility, including guarantees, ranking and collateral, refer to Note 13. Debt Obligations to the Consolidated Financial Statements included in our 2022 Annual Report, which was filed with the SEC on March 14, 2023.

#### CGIC Unsecured Note

On May 9, 2023, in connection with the redemption of the DBMGi Preferred Stock, the Company issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Unsecured Note is due February 28, 2026, and bears interest at 9% per annum through May 8, 2024, 16% per annum from May 9, 2024 to May 8, 2025, and 32% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3 million or 12.5% of the proceeds from certain equity sales. Refer to Footnote 15. Temporary Equity and Equity and 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Infrastructure

As of September 30, 2023, our Infrastructure segment had an aggregate principal amount of outstanding debt of $232.8 million. On August 2, 2022, DBMG negotiated and finalized an amendment to its UMB Revolving Line which included a retrospective change to the terms of the Fixed Coverage Ratio, and an increase in the UMB Revolving Line commitment from $110.0 million to $135.0 million, among other things. Subsequent to quarter end, on November 2, 2023, UMB indicated its intent to extend the maturity date of the Revolving Line from May 31, 2024 to September 30, 2025. As part of the modification, the interest rate spread for the Revolving Line will be increased by 0.35% across all tiers, and the interest rate floor will be increased from 3.0% to 4.25%. No definitive agreements have been signed as of the filing date of this Form 10-Q Quarterly Report. There can be no assurances that the final signed agreements with UMB will close on the aforementioned terms or if at all.

Refer to Note 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional details regarding the indebtedness of our Infrastructure segment.

### Life Sciences

As of September 30, 2023, our Life Sciences segment has aggregate principal outstanding debt of $17.4 million.

During 2022, R2 Technologies entered into an aggregate $10.8 million in 18% notes with Lancer Capital, LLC ("Lancer"), a related party, an entity controlled by Avram A. Glazer, the Chairman of INNOVATE's Board of Directors. In February 2023, R2 Technologies closed on an additional aggregate $0.9 million in 18% notes with Lancer. On March 31, 2023, R2 Technologies entered into an exchange agreement with Lancer, which terminated all prior outstanding notes and simultaneously issued a new 20% note with an aggregate original principal amount of $13.0 million, which comprised of all prior outstanding principal amounts and unpaid accrued interest which was capitalized into the new principal balance. Future interest will be payable upon maturity of the 20% note. During the second and third quarters of 2023, R2 Technologies closed on an additional $2.7 million and $1.7 million, respectively, in 20% notes with Lancer. As of September 30, 2023, the total outstanding principal amount of 20% payable to Lancer was $17.4 million.

In addition, during the third quarter of 2023, R2 entered into an amendment with Lancer to extend the maturity date of all outstanding 20% notes payable to Lancer to the earlier of November 15, 2023 or within 5 business days of the date on which R2 receives an aggregate $20.0 million from the consummation of a debt or equity financing.

### Spectrum

As of September 30, 2023, our Spectrum segment has aggregate principal outstanding debt of $69.7 million.

On December 30, 2022, Broadcasting entered into a Seventh Omnibus Amendment to Secured Notes which, among other things, extended the maturity date of $52.2 million of its Senior Secured Notes, due December 30, 2022 to May 31, 2024. The effective interest rates on the notes range from 12.8% to 19.6%. Interest is capitalized and payable upon maturity of the principal. The $52.2 million of Senior Secured Notes consisted of $19.3 million of 8.5% Senior Secured Notes and $32.9 million of 10.5% Senior Secured Notes. The other terms of the $19.3 million 8.5% Senior Notes remained the same. At the time of the extension, Broadcasting had accrued interest and other fees of $6.9 million. The interest rate on the $32.9 million 10.5% Senior Notes was increased to 11.45% and cumulative accrued interest and exit fees of $17.5 million were capitalized into the principal balance with both note extensions accounted for as debt modification events. All other terms were essentially the same. Total outstanding principal after the refinancing was $69.7 million, and $6.9 million of accrued interest and fees remain accrued, with total exit fees of $7.6 million which were recorded as original issue discount with a corresponding liability reflected in Other Liabilities in the condensed consolidated balance sheet.

Concurrently therewith and as part of the consideration for extending the 10.5% Senior Notes in December 2022, Broadcasting amended warrants to purchase 145,825 shares of common stock of HC2 Broadcasting Holdings, Inc. common stock held by the lenders of the 10.5% Senior Notes by extending the time to exercise such to the second half of 2026 and reducing the exercise price per share (i) from $140.00 to $0.01 in the case of the certain of the warrants and (ii) from $130.00 to $0.01 in the case of the remaining warrants. The warrants have a five-year term and are exercisable at any time. The change in the fair value of the warrants was recorded as original issue discount with a corresponding impact reflected in Non-controlling interest of $3.1 million.

On August 8, 2023, Broadcasting entered into an Eighth Amendment to Secured Notes with its lenders which extended the maturity date of its Senior Secured Notes aggregate principal amount of $69.7 million, from May 31, 2024 to August 15, 2024. In exchange, Broadcasting incurred an additional exit fees of $1.1 million which were recorded as original issue discount with a corresponding liability reflected in Other Liabilities in the Condensed Consolidated Balance Sheet.

Subsequent to quarter end, on November 9, 2023, Broadcasting entered into a Ninth Amendment to its Secured Notes with its lenders which extended the maturity date of its Senior Secured Notes aggregate principal amount of $69.7 million, from August 15, 2024 to August 15, 2025. In exchange, INNOVATE has agreed to utilize proceeds from the sale of any of its existing operations, as allowable under the Company's current agreements and after all other required payments, for repayment of a portion of Broadcasting's Senior Secured Notes, plus an additional exit fee upon such a repayment of $1.0 million if repayment occurs by November 9, 2024, and $2.0 million if repayment occurs after that date. Upon payment of the exit fee, the lenders also agree to return their equity interests in HC2 Broadcasting Holdings, Inc. and its subsidiary equity interests.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional details regarding the indebtedness of our Infrastructure, Life Sciences and Spectrum segments.

### Restrictive Covenants

The indenture governing the 2026 Senior Secured Notes dated February 1, 2021, by and among INNOVATE, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee (the "Secured Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; engage in sale-leaseback transactions; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.

The Company is also required to comply with certain financial maintenance covenants, which are similarly subject to a number of important exceptions and qualifications. These covenants include maintenance of (1) liquidity and (2) collateral coverage.

The maintenance of liquidity covenant provides that the Company will not permit the aggregate amount of (i) all unrestricted cash and Cash Equivalents of the Company and the Subsidiary Guarantors, (ii) amounts available for drawing under revolving credit facilities and undrawn letters of credit of the Company and the Subsidiary Guarantors and (iii) dividends, distributions or payments that are immediately available to be paid to the Company by any of its Restricted Subsidiaries to be less than the Company’s obligation to pay interest for the next six months on the 2026 Senior Secured Notes and all other Debt, including Convertible Preferred Stock mandatory cash dividends or any other mandatory cash pay Preferred Stock but excluding any obligation to pay interest on Convertible Preferred Stock or any other mandatory cash payments on Preferred Stock which, in each case, may be paid by accretion or in-kind in accordance with its terms of the Company and its Subsidiary Guarantors. As of September 30, 2023, the Company was in compliance with this covenant.

The maintenance of collateral coverage provides that the certain subsidiaries' Collateral Coverage Ratio (as defined in the Secured Indenture as the ratio of (i) the Loan Collateral to (ii) Consolidated Secured Debt (each as defined therein)) calculated on a pro forma basis as of the last day of each fiscal quarter may not be less than 1.50 to 1.00. As of September 30, 2023, the Company was in compliance with this covenant.

The instruments governing the Company’s Preferred Stock also limit the Company’s and its subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.

The Company has conducted its operations in a manner that has resulted in compliance with the Secured Indenture; however, compliance with certain financial covenants for future periods may depend on the Company or one or more of the Company’s subsidiaries undertaking one or more non-operational transactions, such as the management of operating cash outflows, a monetization of assets, a debt incurrence or refinancing, the raising of equity capital, or similar transactions. If the Company is unable to remain in compliance and does not make alternate arrangements, an event of default would occur under the Company’s Secured Indenture which, among other remedies, could result in the outstanding obligations under the indenture becoming immediately due and payable and permitting the exercise of remedies with respect to the collateral. There is no assurance the Company will be able to complete any non-operational transaction it may undertake to maintain compliance with covenants under the Secured Indenture or, even if the Company completes any such transaction, that it will be able to maintain compliance for any subsequent period.

The UMB Term Loan and UMB Revolving Line associated with our Infrastructure segment contains customary restrictive and financial covenants related to debt levels and performance, including a Fixed Coverage Ratio covenant, as defined in the agreement.

As of September 30, 2023, we were in compliance with the covenants of our debt agreements.

### Summary of Consolidated Cash Flows

The below table summarizes the cash provided by or used in our activities and the amount of the respective changes between the years (in millions):

|  | September 30 2023 | 2022 | Increase / (Decrease) |
| --- | ---: | ---: | ---: |
| Cash used in operating activities | (34.7) | (72.2) | 37.5 |
| Cash provided by (used in) investing activities | 41.2 | (18.3) | 59.5 |
| Cash (used in) provided by financing activities | (30.6) | 73.2 | (103.8) |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | (1.0) | (2.5) | 1.5 |
| Net decrease in cash and cash equivalents, including restricted cash | $(25.1) | $(19.8) | $(5.3) |

#### Operating Activities

Cash used in operating activities was $34.7 million for the nine months ended September 30, 2023, as compared to $72.2 million for the nine months ended September 30, 2022, a decrease in cash used of $37.5 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and operating margins, but can also be affected by working capital needs associated with our operations. For the nine months ended September 30, 2023, the decrease in cash used in operating activities was primarily due to a net decrease in working capital cash outflows, primarily from changes in contract-related assets and liabilities at our Infrastructure segment, which was partially offset by an increase in net loss after non-cash adjustments.

#### Investing Activities

Cash provided by investing activities was $41.2 million for the nine months ended September 30, 2023 as compared to cash used in investing activities of $18.3 million for the nine months ended September 30, 2022, an improvement of $59.5 million. The improvement in cash provided by investing activities was primarily driven by the $54.2 million of gross cash proceeds received from the sale of New Saxon's 19% investment in HMN on March 6, 2023. Capital expenditures, net of disposals for the nine months ended September 30, 2023 were $12.4 million, as compared to $14.4 million for nine months ended September 30, 2022, a net decrease in cash used in PP&E activity of $2.0 million, primarily due to the completion of the Spectrum station build-out subsequent to the comparable period in 2022. Additionally, the nine months ended September 30, 2022 had included a $4.5 million loan to MediBeacon in the first quarter of 2022, while the current period includes $1.0 million in loans to MediBeacon in the third quarter of 2023.

#### Financing Activities

Cash used in financing activities was $30.6 million for the nine months ended September 30, 2023 as compared to cash provided by financing activities of $73.2 million for the nine months ended September 30, 2022, an increase in cash used of $103.8 million. The increase in cash used in financing activities was primarily driven by a decrease in net proceeds from our credit facilities of $81.7 million, primarily from a decrease in net proceeds from Infrastructure's UMB Revolving Line of $66.7 million and a decrease in net proceeds from our Non-Operating Corporate Revolving Line of Credit of $15.0 million. In addition, during the nine months ended September 30, 2023, we made $15.9 million in distributions to non-controlling interests and redeemable non-controlling interests related to the sale of New Saxon's 19% investment in HMN on March 6, 2023 and also made a $7.0 million payment in connection with the repurchase the DBMGi Series A Preferred Stock. Compared to the prior period, proceeds from other debt obligations decreased by $4.6 million, which was partially offset by a decrease in principal payments on other debt obligations.

### Infrastructure

#### Cash Flows

Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.

DBMG is required to make monthly or quarterly interest payments on all of its debt. Based upon the September 30, 2023 debt balance, DBMG anticipates that its interest payments will be approximately $3.3 million for the fourth quarter of 2023.

### Off- Balance Sheet Arrangements

We may enter into certain off-balance sheet arrangements in the ordinary course of business. Our off-balance sheet transactions may include, but are not limited to: leases that have not yet commenced, short-term leases, liabilities associated with non-cancelable operating leases with durations of less than twelve months, letter of credit obligations, surety, performance or payment bonds entered into in the normal course of business, and liabilities associated with multi-employer pension plans. Refer to Note 9. Leases, Note 13. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on leases and letters of credit and performance and/or payment bonds, respectively.

### New Accounting Pronouncements

For information on new accounting pronouncements refer to Note 2. Summary of Significant Accounting Policies of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

### Critical Accounting Estimates

There have been no material changes in the Company’s critical accounting policies during the period ended September 30, 2023. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2022 Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023.

### Related Party Transactions

For a discussion of our Related Party Transactions, refer to Note 16. Related Parties of the unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.

Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing the integration of financial reporting of acquired or target businesses with INNOVATE or the applicable subsidiary of INNOVATE, completing future acquisitions and dispositions, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC March 14, 2023 and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.

### INNOVATE Corp. and Subsidiaries

Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- the recent passing of our Chief Executive Officer, President and Director and the successful transition of his management responsibilities;
- our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;
- the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;
- the impact of covenants in the Indenture governing INNOVATE’s 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Unsecured Note and Revolving Credit Agreement, the Certificates of Designation governing INNOVATE’s Preferred Stock and all other subsidiary debt obligations as summarized in Note 13. Debt Obligations to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC March 14, 2023 and future financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;
- the effect of the novel coronavirus (“COVID-19”) pandemic and related governmental responses on our business, financial condition and results of operations;
- our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;
- our dependence on certain key personnel;
- bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;
- our possible inability to hire and retain qualified executive management, sales, technical and other personnel;
- the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;
- the impact of recent supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;
- the impact of a higher interest rate environment;
- the effects related to or resulting from Russia's military action in Ukraine, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;
- increased competition in the markets in which our operating segments conduct their businesses;
- limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;
- our ability to effectively increase the size of our organization, if needed, and manage our growth
- the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;
- our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;
- the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved
- uncertain global economic conditions in the markets in which our operating segments conduct their businesses;
- the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;
- potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes in the frequency and severity of weather patterns;
- the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;
- tax consequences associated with our acquisition, holding and disposition of target companies and assets;
- our ability to remain in compliance with the listing standards of the New York Stock Exchange;
- the ability of our operating segments to attract and retain customers;
- our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;
- management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;
- management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;
- our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, including the shut-down of our Network business by our Spectrum segment, that we may make in the future and the effect of any such dispositions or sales on our results of operations;
- the possibility of indemnification claims arising out of divestitures of businesses; and
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all.

### Infrastructure / DBM Global Inc.

Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- our ability to maintain efficient staffing and productivity as well as delays and cancellations as a result of the COVID-19 pandemic;
- cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;
- uncertain timing and funding of new contract awards, as well as project cancellations;
- potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;
- changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- the impact of inflationary pressures;
- adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;
- risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;
- its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;
- its ability to settle or negotiate unapproved change orders and claims;
- fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate;
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; and
- lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts or to finance expenditures prior to the receipt of payment for the performance of contracts.

### Life Sciences / Pansend Life Sciences, LLC

Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Life Sciences segment’s ability to invest in development stage companies;
- our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;
- medical advances in healthcare and biotechnology;
- governmental regulation in the healthcare industry; and
- our Life Science's segment possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all.

### Spectrum / HC2 Broadcasting Holdings Inc.

Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Spectrum segment’s ability to operate in highly competitive markets and maintain market share;
- our Spectrum segment’s ability to effectively implement its business strategy or be successful in the operation of its business;
- our Spectrum segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all;
- new and growing sources of competition in the broadcasting industry; and
- FCC regulation of the television broadcasting industry.

We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.

## Controls and procedures

As filed, 1,613 characters.

### Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2023, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,898 characters.

Other than as set forth below, there have been no material changes in our risk factors from those disclosed in Part 1, Item 1A of our Fiscal Year 2022 Form 10-K, which was filed with the SEC on March 14, 2023. See "Risk Factors" in Item 1A of Part I of such Fiscal Year 2022 Form 10-K for a complete description of the material risks we face.

***Bank failures or other similar events could adversely affect our and our customers' and vendors' liquidity and financial performance.***

We maintain domestic cash deposits in Federal Deposit Insurance Corporation ("FDIC") insured banks, in excess of FDIC insurance limits. Bank failures or other similar events could disrupt our access to bank deposits or otherwise adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S. or applicable foreign government in the event of a failure or liquidity crisis.

Our customers and vendors may suffer similar adverse effects from a bank failure. Any resulting adverse effects to our customers could reduce the demand for our services or affect our allowance for doubtful accounts and collectability of accounts receivable. Adverse effects to our vendors could affect our ability to receive the resources and supplies we need for our business. These factors could materially affect our future financial results.

In addition, instability, liquidity constraints or other distress in the financial markets, including the effects of bank failures or similar adverse developments could impair the ability of one or more of the banks participating in our current credit facilities from honoring their commitments. This could have an adverse effect on our business if we were not able to replace those commitments or to locate other sources of liquidity on acceptable terms.

***Loss of our key management or other personnel, including the recent unexpected passing of our Chief Executive Officer, President and Director, could adversely impact our business.***

We believe that the future success of INNOVATE and its operating subsidiaries is largely dependent and will depend to a significant extent upon the performance, skills, experience and efforts of our senior management and certain other key personnel. If, for any reason, one or more senior executives or key personnel were not to remain active in our Company, our results of operations could be adversely affected.

On July 23, 2023, we announced the unexpected passing of Wayne Barr, our President, Chief Executive Officer and Director. Mr. Barr had served as a director of INNOVATE since January 2014 and as CEO since November 2020. Following Mr. Barr’s death, on July 25, 2023, Paul K. Voigt was named Interim Chief Executive Officer of the Company. Mr. Voigt has served as Senior Managing Director of Investments at Lancer Capital since 2019. From 2014 to 2018, Mr. Voigt served as Senior Managing Director of Investments of the Company and was involved with sourcing deals and capital raising for the Company.

The executive management teams that lead our subsidiaries are also highly experienced and possess extensive skills in their relevant industries. The ability to retain key personnel is important to our success and future growth. Competition for these professionals can be intense, and we may not be able to retain and motivate our existing officers and senior employees, and continue to compensate such individuals competitively. The unexpected loss of the services of one or more of these individuals, whether due to competition, distraction caused by personal matters or otherwise, could have a detrimental effect on the financial condition or results of operations of our businesses, and could hinder the ability of such businesses to effectively compete in the various industries in which we operate.

Filed Nov 9, 2023.
Source: SEC EDGAR, the filing index for accession 0001006837-23-000128. Last ingested by Listed: Nov 14, 2026, 23:42 ET. No prices; not investment advice.
